Vir Biotechnology Phase 3 Trial Meets Hepatitis Delta Goal
San Francisco, California, United States, November 9, 2026 Vir Biotechnology, Inc. has announced positive topline results from its pivotal...
Hepatitis Delta Virus
Advertisement
Assembly Bio Doses First Participants in Phase 2 ABI-6250 Study
South San Francisco, California — October 29, 2026 Assembly Biosciences, Inc. announced that the first two participants have been...
Mirum Advances Brelovitug in Phase 3 HDV Trial
Foster City, California, U.S., September 28, 2026 Mirum Pharmaceuticals has announced a major clinical-development milestone for brelovitug, an investigational...
Assembly Bio Expands ABI-6250 Into Liver Diseases
SOUTH SAN FRANCISCO, Calif., May 22, 2026 Assembly Biosciences announced plans to expand the clinical development of ABI-6250, its...
FDA Grants Historic Approval to Gilead’s Hepcludex for HDV
Foster City, California, USA – May 21, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration...
Advertisement
